Studies have shown immediate-release opioids can be used supplementally when transdermal buprenorphine is being used to manage moderate-to-severe chronic pain.
The study cleared up confusion as whether or not immediate-release opioids would properly function with buprenorphine, which may displace or prevent competing mu-opioid agonists from binding.
More Articles on Anesthesia:
Drug EXPAREL Reduces Pain, Adverse Opioid Side Effects
Donald Bell Elected to Chair Tennessee Board of Nursing
Dr. Andrew Greenfield Named Senior VP of Anesthesiology at Sheridan Healthcare
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
